alt

20th Conference on Retroviruses and Opportunistic Infections (CROI 2013)

March 3-6, 2013, Atlanta

CROI 2013: Health Insurance Coverage Linked to HIV Viral Load Suppression [VIDEO]

Whether people with HIV have health insurance -- and the type of coverage they have -- influences the likelihood of viral suppression, according to a poster presentation Tuesday at the 20th Conference on Retroviruses and Opportunistic Infections (CROI 2013) in Atlanta.

alt

Read more:

Coverage of the 2013 Conference on Retroviruses and Opportunistic Infections

HIVandHepatitis.com coverage of the 20th Conference on Retroviruses and Opportunistic Infections (CROI 2013), March 3-6, 2013, in Atlanta.

Conference highlights include HIV experimental therapies and treatment strategies, HIV cure research, HIV-related conditions and complications, treatment as prevention and PrEP, new treatments for hepatitis C, and HIV/HBV and HIV/HCV coinfection.

Full listing by topic

HIVandHepatitis.com CROI 2013 conference section

3/4/13

alt

CROI 2013: VOICE Trial's Disappointing Result Poses Big Questions for PrEP

The failure of one of the largest trials yet conducted of HIV drug-based prevention methods poses questions for how to turn vaginal microbicides and oral pre-exposure prophylaxis (PrEP) into methods people can actually use, the 20th Conference on Retroviruses and Opportunistic Infections (CROI 2013) in Atlanta heard today.

alt

Read more:

CROI 2013: Progress in Hepatitis C Drug Development [VIDEO]

Hepatitis C and its treatment has been a key focus at the 20th Conference on Retroviruses and Opportunistic Infections(CROI 2013), taking place this week in Atlanta. Investigators gave an overview of their research and projections about forthcoming approvals of direct-acting antiviral agents at a morning press conference on Monday.

alt

Read more:

CROI 2013: Development of Small Molecules for HIV Eradication [VIDEO]

Research towards a cure for HIV is a key theme of the 20th Conference on Retroviruses and Opportunistic Infections (CROI 2013), taking place this week in Atlanta. One of the many approaches under study is the use of small molecules to bring resting HIV out of latency, in an effort to ultimately eradicate the virus from the body.alt

Read more: